SecBot SecBot
144 ·Filed Jun 23, 2026

NUVB

Nuvation Bio Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001950047-26-006425
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for the actual sale on Form 4, but given the 10b5-1 plan and small relative size, no immediate impact expected.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
NUVB ▼ -6.04% at T+60d
NEUTRAL call -6.04% · α vs SPY -8.88% · entry $6.46 → $6.07
Entry = T+0 close
Jun 23, 2026
via day close
T+1d
-10.06%
call -10.06% · α -10.21%
$5.81
settled 4mo ago
T+5d
-16.10%
call -16.10% · α -17.81%
$5.42
settled 4mo ago
T+20d
+1.39%
call +1.39% · α -0.54%
$6.55
settled 3mo ago
T+60d
-6.04%
call -6.04% · α -8.88%
$6.07
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Insider Kerry Wentworth (Officer) filed a Form 144 on June 23, 2026, signaling intent to sell 63,000 shares (~$362,880 at estimated price). The shares would be acquired via stock option exercise and sold through a 10b5-1 plan. Prior sales under the same 10b5-1 plan include 36,750 shares on Apr 17, 2026 and 200,000 shares on Apr 6, 2026. The plan was adopted on Dec 4, 2025. The filing is a routine pre-arranged sale under a 10b5-1 plan and does not indicate new insider concern.

Key Facts

  • Insider Kerry Wentworth (Officer) intends to sell 63,000 shares via a 10b5-1 plan adopted 12/04/2025.
  • Estimated sale value: ~$362,880 (based on filing price of $5.76/share).
  • Prior 10b5-1 sales: 36,750 shares on 04/17/2026 and 200,000 shares on 04/06/2026.
  • The sale is part of a pre-arranged trading plan, not a discretionary decision.
  • Market cap is ~$2.0B; the planned sale represents ~0.02% of shares outstanding.

Financial Impact

Planned sale of ~$363K (63,000 shares at ~$5.76), immaterial relative to $2.0B market cap.

dilutioninsider ownership

Risk Factors

  • No material risk—planned sale is pre-arranged and small.
  • Repeated insider selling under the same plan is not a signal of deterioration.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006425
Document: 0001950047-26-006425-index.html0001950047-26-006425
Document: 0001950047-26-006425.txt0001950047-26-006425
8 reports for NUVB
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NUVB — sortable, filterable
TypeNow
Oct 21, 2026
4d ago
Press Release
NEUTRAL ★ 1/10
$4.70awaiting T+60—$4.57 (−2.87%)
Aug 6, 2026
11w ago
8-K
MIXED ★ 5/10
$6.11awaiting T+60—$4.57 (−25.29%)
Jun 26, 2026
17w ago
424B5
BEARISH ★ 6/10
$5.61 $6.10▼ −8.73%▼ −4.35%$4.57 (+18.63%)
Jun 23, 2026
17w ago
144
BEARISH ★ 6/10
$6.46 $6.07▲ +6.04%▲ +8.88%$4.57 (+29.33%)
Jun 23, 2026
17w ago
144
NEUTRAL ★ 3/10
$6.46 $6.07▼ −6.04%▼ −8.88%$4.57 (−29.33%)
May 4, 2026
24w ago
8-K
MIXED ★ 6/10
$4.83 $6.70▲ +38.72%▲ +35.98%$4.57 (−5.49%)
Apr 21, 2026
26w ago
DEFA14A
NEUTRAL ★ 2/10
$5.11 $5.64▲ +10.37%▲ +3.47%$4.57 (−10.67%)
Apr 17, 2026
27w ago
144
NEUTRAL ★ 3/10
$5.12 $5.90▲ +15.23%▲ +8.46%$4.57 (−10.84%)
Showing 8 of 8

US Market Status

Market Open — Closes in 5h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026